Source:http://linkedlifedata.com/resource/pubmed/id/20179522
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2010-2-24
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1528-1175
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
112
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
760-1; author reply 762-3
|
pubmed:meshHeading |
pubmed-meshheading:20179522-Blood Transfusion,
pubmed-meshheading:20179522-Coronary Artery Bypass,
pubmed-meshheading:20179522-Evidence-Based Medicine,
pubmed-meshheading:20179522-Humans,
pubmed-meshheading:20179522-Immune System,
pubmed-meshheading:20179522-Neoplasms,
pubmed-meshheading:20179522-Survival Analysis
|
pubmed:year |
2010
|
pubmed:articleTitle |
The evidence shows that allogeneic transfusion is associated with reduced survival after coronary artery bypass surgery.
|
pubmed:publicationType |
Letter,
Comment
|